A National, Multicenter, Open Label, Randomized Phase III study for Induction therapy with BORTEZOMIB/ LENALIDOMIDE/ DEXAMETHASONE (VRD-GEM) followed by High-dose Chemotherapy with MELPHALAN-200 (MEL-200) vs. BUSULFAN/MELPHALAN (BUMEL) and Consolidation t
Read time: 1 mins
Last updated:9th Jul 2013
Rate of complete remission (CR) with negative immunofixation after each stage of treatment (induction and consolidation autotransplantation). Evaluation of minimal residual disease (MRD) in patients with negative immunofixation RC-after each stage of treatment (induction and consolidation autotransplantation). Overall survival (OS) after PBSCT with BuMel vs. MEL-200. To evaluate the safety and tolerability of induction and consolidation treatment.
|Study start date||2013-07-09|